Don't Expect Siliq to Change Practice in the Crowded Psoriasis Market

Siliq (sil-EEK, brodalumab) will be a new biologic for moderate to severe plaque psoriasis.

It'll join the other interleukin blockers Cosentyx, Stelara, Taltz, and Tremfya...along with TNF-alpha blockers Remicade, Enbrel, Humira.

Weigh pros and cons when a biologic is needed for psoriasis.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote